How to Prepare Registration Dossiers for Medical Device Registration in South Korea

Key Takeaways

To answer the question of how registration dossiers for medical device registration in South Korea should be prepared, a company should first confirm the target country, the product's risk class, the applicable regulatory pathway and the dossiers it already holds, and only then assess the technical documentation, quality system evidence, labelling and instructions for use (IFU), local representative arrangements, clinical evidence and post-market maintenance obligations. AIMEILI recommends completing a dossier gap assessment before formal submission, so that the project timeline is not extended by unclear classification, missing documentation or undefined authorization arrangements.

For Chinese medical device manufacturers, the more reliable approach is to complete product classification and a dossier gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market documentation can be reused. Registration in a target market typically affects technical documentation, the authorized representative, importer cooperation, label language, quality system evidence and subsequent change maintenance at the same time. If a project advances purely on the basis of "which documents must be submitted", deficiencies or rework are likely to arise in model coverage, evidence chain consistency, label claims and certificate control. AIMEILI recommends planning this question within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets, rather than rebuilding dossiers country by country.

Compiled from AIMEILI's regulatory practice question bank, the AIMEILI Medical Device International Registration Knowledge Base and publicly available regulatory information; specific projects should be based on the latest requirements of the target country's regulatory authority and the product's documentation base.

Applicable Scenarios and Core Questions

Companies searching for "how to prepare registration dossiers for medical device registration in South Korea" are usually not looking for a conceptual explanation. What they need to determine is whether their existing documentation can support a submission in the target market, whether a local agent or authorized representative is required, why timelines become extended, and which issues could affect the launch plan. Behind this question there are typically several linked topics: product classification, registration pathway, evidence chain, label localization and post-market maintenance responsibility.

If a company plans to enter several GHWP member states at the same time, or markets in Southeast Asia, the Middle East and Latin America, answering the process for a single country is not enough. A more valuable approach is to first turn the core technical file, quality system evidence, performance verification, clinical evidence and IFU into reusable versions, and then localize them according to each country's regulatory requirements.

Regulatory Determination Logic

A company should first confirm the intended use, mechanism of action, use scenario, method and duration of body contact, whether the device is sterile, whether it is active, and whether it contains software or has IVD characteristics, and then determine the risk class and the submission pathway. Once the pathway is judged incorrectly, everything that follows — translation, notarization, authorization, testing and supplementary documentation — will move in the wrong direction.

For a target-market project, the applicant entity and the boundaries of local responsibility must also be confirmed: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes and who maintains renewal documentation. If these issues are left vague in a commercial contract, market control can easily be affected later.

Dossiers and Evidence

Typical documentation includes the product description, model and specification matrix, intended use, basis for risk classification, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labelling and IFU, authorization documents, existing registration certificates, manufacturer's declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, the models covered by test reports, the scope of application of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must all support one another. A regulatory authority is concerned with whether the device is safe, effective and traceable for its intended use — not with how many documents a company has uploaded.

Common Mistakes

The most common problem is treating a registration project as a simple document submission, without first clarifying product classification, evidence coverage and local responsibility relationships.

• Submitting translated NMPA documentation directly, without reorganizing the evidence according to the target market pathway.
• Listing too many models and specifications while test reports, clinical evidence or labels do not cover them adequately.
• Selecting a local agent purely on the basis of sales cooperation, without defining regulatory responsibility, certificate control and post-market maintenance duties.
• Inconsistency between labels, IFU, promotional materials and registration dossier claims, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country dossier reuse in advance, resulting in repeated preparation in each country and inflated cost and timelines.

Company Preparation Checklist

Before starting a project, companies are advised to use an internal checklist to confirm the documentation base, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documentation can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English IFU.
• Confirm the local agent's or authorized representative's duties, fees, certificate control and exit arrangements.
• Establish a target-country gap assessment table identifying what must be retested, translated, notarized or supported by additional declarations.

AIMEILI's View

AIMEILI recommends that companies not treat target-market registration as a one-off document submission, but manage it as an overseas market access programme. For companies entering multiple countries, building a clear core technical file and evidence matrix first and then converting it to each country's requirements is usually faster, more stable and better suited to later changes and renewals than patching documentation country by country.

From a project management perspective, three things should be controlled early: first, product classification and pathway determination; second, consistency of the dossier evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three elements are unclear, a project may still go back and forth during deficiency responses, agent communication and post-market maintenance — even if the dossier appears substantial.

Frequently Followed-Up Questions

Can domestic documentation be used directly for target-market registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as is. Companies need to adjust the dossier structure, language, labelling, authorization documents and evidence chain in line with local regulatory requirements.

When is the best time to start a gap assessment?

Immediately after the target market and product list are confirmed. The earlier the gap assessment is completed, the earlier retesting, translation, label adaptation and agent selection can be arranged.

Why does the choice of local agent affect registration quality?

A local agent is typically involved in registration communication, changes, renewals and post-market event handling. Unclear rights and responsibilities can affect certificate control and the stability of the market thereafter.

Project Execution Recommendations

When executing this type of registration project, companies should set up a project register that manages the product list, model and specifications, registration pathway, document owners, translation status, testing status, local agent communication records and expected submission dates in a single table. This makes documentation gaps visible in good time and helps management judge whether the project will affect the launch plan.

Companies that already hold registrations in several countries should also build an evidence reuse matrix that identifies which documents can serve as core evidence and which must be reissued or supplemented for a specific country. In particular, the IFU, clinical evaluation, risk management, performance verification and quality system certificate must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a dossier gap assessment table.
• Define the local agent and certificate control arrangements.
• Track translation, notarization, testing and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality System and Evidence Consistency

From a registration review perspective, quality system documentation is not an isolated certificate. Regulatory authorities generally examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent with one another. If the scope covered by the ISO 13485 certificate does not match the device being submitted, or if the manufacturing address, model and specification or IFU version differs from the test report, additional clarification may be required even when a large volume of documentation has been prepared.

Before submission, companies should create an evidence consistency checklist that maps product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU version and quality system certificate item by item. This may appear basic, but it significantly reduces the probability of deficiency letters — particularly for projects submitted simultaneously in several GHWP member states or across multiple product families.

Localization and Representative Responsibilities

Target-market registration projects usually involve a local agent, authorized representative, importer or registration holder arrangement. Companies need to confirm in advance whether the local partner is only responsible for submitting documents, or whether it also handles regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and the stability of the market thereafter.

Labels, IFUs and authorization documents also cannot simply be translated. Companies should verify local language requirements, the boundaries of product claims, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is converting reusable evidence into a submission structure acceptable in the target country, rather than writing a separate set of isolated documents.

Post-Market Maintenance and Long-Term Planning

Registration approval does not mean the compliance work is finished. Companies must also maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining the certificate but neglect post-market maintenance; when manufacturing site changes, model extensions, IFU updates or agent replacements occur later, the certificate and market sales activities can become disconnected.

AIMEILI recommends managing this question as part of an annual international registration plan: first set target market priorities, then build a reusable dossier package and a country gap list, and finally schedule submission, deficiency response, post-market maintenance and renewal milestones. The value of this approach lies not only in improving efficiency for a single country, but in enabling companies to build a repeatable overseas compliance capability and reduce the cost of starting from scratch each time they enter a new market.

Related Reading

• How Should a Local Representative Be Selected for Medical Device Registration in Brazil?
• How Are Authorized Representative Responsibilities Divided for Medical Device Registration in Brazil?
• Why Do Registration Timelines for Medical Device Registration in Brazil Become Extended?
• What Are the Common Reasons for Deficiency Letters in Brazilian Medical Device Registration?
• How Is Post-Market Surveillance Conducted for Medical Device Registration in Brazil?
• When Must Registration Changes Be Notified for Medical Device Registration in Brazil?

Previous: What Should Be Done When Quality System Evidence Is Inconsistent for Medical Device Registration in India?

Next: How Is Product Classification Determined for Medical Device Registration in South Korea?

Content Review and Applicable Boundaries

Content author: AIMEILI Regulatory Editorial Team. Professional review: AIMEILI Medical Device International Registration Project Team.

Source principles: priority is given to official regulatory authorities, international organizations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting judgment.

Applicable boundaries: this article is intended for preliminary understanding, dossier preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.